A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 open-label extension (OLE) study in patients diagnosed with Prader-Willi
Syndrome (PWS) who completed the Maintenance Period of the randomized, placebo-controlled
Phase 2/3 study SCOUT-015.
The primary objective of this study is to assess the long-term safety and tolerability of
RAD011.